Kim Forest Enterprise Co., Ltd. (TPE:6645)
17.35
-0.15 (-0.86%)
At close: Feb 11, 2026
Kim Forest Enterprise Revenue
Kim Forest Enterprise had revenue of 144.36M TWD in the quarter ending September 30, 2025, with 15.91% growth. This brings the company's revenue in the last twelve months to 531.58M, up 12.43% year-over-year. In the year 2024, Kim Forest Enterprise had annual revenue of 501.53M with 20.85% growth.
Revenue (ttm)
531.58M
Revenue Growth
+12.43%
P/S Ratio
1.98
Revenue / Employee
n/a
Employees
n/a
Market Cap
1.05B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 501.53M | 86.52M | 20.85% |
| Dec 31, 2023 | 415.01M | -255.58M | -38.11% |
| Dec 31, 2022 | 670.59M | 69.92M | 11.64% |
| Dec 31, 2021 | 600.67M | 297.78M | 98.31% |
| Dec 31, 2020 | 302.90M | 32.34M | 11.95% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Lotus Pharmaceutical | 18.66B |
| PharmaEssentia | 13.82B |
| Ma Kuang Healthcare Holding | 1.10B |
| Anxo Pharmaceutical | 883.22M |
| Prince Pharmaceutical | 798.27M |
| Level Biotechnology | 753.30M |
| Puriblood Medical | 117.35M |
| Caliway Biopharmaceuticals | 34.99M |